UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez

Company Presents HOPE-B Data At R&D Day

 
• By Alaric DeArment
  
Hemophilia_525478450_1200.jpg
uniQure presented an update to data from its Phase III HOPE-B study of etranacogene dezaparvovec in hemophilia B • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies